Dogwood Therapeutics provides 2025 progress update Jan 20, 2026 08:38AM
Dogwood Therapeutics (DWTX) files for 6.43M share offering by selling stockholders Jan 15, 2026 04:22PM
Dogwood Therapeutics raises $12.5 million in registered direct offering Jan 12, 2026 08:33AM
Dogwood Therapeutics files patent for synthetic Halneuron manufacturing Dec 2, 2025 08:06AM
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 Dec 2, 2025 08:00AM


Nov 11, 2025 08:45AM Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Nov 6, 2025 04:28PM Dogwood Therapeutics (DWTX) Misses Q3 EPS by 820c
Nov 6, 2025 04:28PM Dogwood Therapeutics (DWTX) Misses Q3 EPS by 820c
Oct 30, 2025 09:15AM Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Oct 14, 2025 08:45AM Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
Oct 7, 2025 08:45AM Dogwood Therapeutics CMO to present pain research at summit
Oct 7, 2025 08:45AM Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
Oct 1, 2025 04:20PM Dogwood Therapeutics (DWTX) files for 28.04M share offering by selling stockholders
Sep 30, 2025 06:49AM Dogwood Therapeutics, Inc. (DWTX) PT Raised to $12 at H.C. Wainwright
Sep 29, 2025 07:19AM Dogwood Therapeutics licenses SP16 for cancer pain treatment
Aug 13, 2025 06:53PM Dogwood Therapeutics (DWTX) Tops Q2 EPS by 199c
Aug 7, 2025 01:10PM Dogwood Therapeutics enrolls 50 patients in Halneuron pain trial
May 8, 2025 05:09PM Dogwood Therapeutics (DWTX) Misses Q1 EPS by 845c
May 1, 2025 08:30AM Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Apr 23, 2025 06:35AM H.C. Wainwright Upgrades Dogwood Therapeutics, Inc. (DWTX) to Buy
Apr 11, 2025 09:15AM Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance
Apr 3, 2025 09:00AM Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance
Mar 18, 2025 08:45AM Dogwood Therapeutics (DWTX) Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Mar 13, 2025 09:02AM Dogwood Therapeutics (DWTX) Prices 579K Share Offering at $8.26/sh
Mar 12, 2025 08:31AM Dogwood Therapeutics (DWTX) Announces Conversion of Existing $19.5M in Debt to Equity
Jan 23, 2025 12:42PM Dogwood Therapeutics (DWTX) Halted on Volatility, Up 552%
Nov 18, 2024 08:46AM Dogwood Therapeutics (DWTX) Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Oct 30, 2024 09:16AM Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance
Oct 7, 2024 07:06AM Virios Therapeutics (VIRI) to merge with Wex Pharmaceuticals, form Dogwood Therapeutics (DWTX)